Sanchita Bhatnagar

Sanchita Bhatnagar

Auto-generated profile, based on publicly available information

Sanchita Bhatnagar

University of California Davis School of Medicine

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2008 in Traffic
Verified
Journal Article
Open access
PDF file
Jeffrey S. SchoreyJeffrey S. Schorey
Jeffrey S. Schorey
SBSanchita Bhatnagar
Sanchita Bhatnagar
Exosomes are the newest family member of ‘bioactive vesicles’ that function to promote intercellular communication. Exosomes are derived from the fusion of multivesicular bodies with the plasma membrane and extracellular release of the intraluminal vesicles. Recent studies have focused on the biogenesis and composition of exosomes as well as regulation of exosome release. Exosomes have been shown to be released by cells of hematopoietic and non‐hematopoietic origin, yet their function remains enigmatic. Much of the prior work has focused on exosomes as a source of tumor antigens and in presentation of tumor antigens to T cells. However, new studies have shown that exosomes might also promote cell‐to‐cell spread of infectious agents. Moreover, exosomes isolated from cells infected with various intracellular pathogens, including Mycobacterium tuberculosis and Toxoplasma gondii, have been shown to contain microbial components and can promote antigen presentation and macrophage activation, suggesting that exosomes may function in immune surveillance. In this review, we summarize our understanding of exosome biogenesis but focus primarily on new insights into exosome function. We also discuss their possible use as disease biomarkers and vaccine candidates.

1 November 2007 in Blood
Verified
Journal Article
Open access
PDF file
SBSanchita Bhatnagar
Sanchita Bhatnagar
KSKazuhiko Shinagawa
Kazuhiko Shinagawa
FCFrancis J. Castellino
Francis J. Castellino
Jeffrey S. SchoreyJeffrey S. Schorey
Jeffrey S. Schorey
Intracellular pathogens and the molecules they express have limited contact with the immune system. Here, we show that macrophages infected with intracellular pathogens Mycobacterium tuberculosis, M bovis BCG, Salmonella typhimurium, or Toxoplasma gondii release from cells small vesicles known as exosomes which contain pathogen-associated molecular patterns (PAMPs). These exosomes, when exposed to uninfected macrophages, stimulate a proinflammatory response in a Toll-like receptor– and myeloid differentiation factor 88–dependent manner. Further, exosomes isolated from the bronchoalveolar lavage fluid (BALF) of M bovis BCG–infected mice contain the mycobacteria components lipoarabinomannan and the 19-kDa lipoprotein and can stimulate TNF-α production in naive macrophages. Moreover, exosomes isolated from M bovis BCG– and M tuberculosis–infected macrophages, when injected intranasally into mice, stimulate TNF-α and IL-12 production as well as neutrophil and macrophage recruitment in the lung. These studies identify a previously unknown function for exosomes in promoting intercellular communication during an immune response to intracellular pathogens, and we hypothesize that extracellular release of exosomes containing PAMPs is an important mechanism of immune surveillance.

1 August 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SBSanchita Bhatnagar
Sanchita Bhatnagar
Jeffrey S. SchoreyJeffrey S. Schorey
Jeffrey S. Schorey
Mycobacterium avium is a major opportunistic pathogen in HIV-positive individuals and is responsible for increased morbidity and mortality in AIDS patients. M. avium express glycopeptidolipids (GPLs) as a major cell wall constituent, and recent studies suggest that GPLs play an important role in M. avium pathogenesis. In the present study we show that M. avium-infected macrophages release GPLs, which are trafficked from the phagosome through the endocytic network to multivesicular bodies. Prior studies have shown that multivesicular bodies can fuse with the plasma membrane releasing small 50 to 100 nm vesicles known as exosomes. We found that M. avium-infected macrophages release exosomes containing GPLs leading to the transfer of GPLs from infected to uninfected macrophages. Interestingly, exosomes isolated from M. avium-infected but not from uninfected macrophages can stimulate a proinflammatory response in resting macrophages. This proinflammatory response is dependent on Toll like receptor (TLR) 2, TLR4, and MyD88 suggesting that released exosomes contain M. avium-expressed TLR ligands. Our studies are the first to demonstrate that exosomes isolated from mycobacteria-infected macrophages can induce a proinflammatory response, and we hypothesize that exosomes play an important role in immune surveillance during intracellular bacteria infections.

24 November 2014 in Nature
Verified
Journal Article
Open access
PDF file
SBSanchita Bhatnagar
Sanchita Bhatnagar
CGClaude Gazin
Claude Gazin
LCLynn Chamberlain
Lynn Chamberlain
JOJianhong Ou
Jianhong Ou
XZXiaochun Zhu
Xiaochun Zhu
MGMichael R. Green
Michael R. Green
The RING finger protein TRIM37 is encoded by a gene that is amplified in certain breast cancers, but its function is unknown; here, it is shown to mono-ubiquitinate histone H2A and repress gene expression, and to function as a breast cancer oncoprotein. The RING finger protein TRIM37 is encoded by a gene amplified in certain breast cancers, but its function was unknown. Michael Green and colleagues now report that TRIM37 can mono-ubiquitinate histone H2A and functions in gene regulation by associating with the polycomb complex PRC2. TRIM37 is proposed to promote transformation by altering the specificity of PRC2 and facilitating silencing of tumour suppressors and other genes. The TRIM37 (also known as MUL) gene is located in the 17q23 chromosomal region, which is amplified in up to ∼40% of breast cancers1. TRIM37 contains a RING finger domain, a hallmark of E3 ubiquitin ligases2, but its protein substrate(s) is unknown. Here we report that TRIM37 mono-ubiquitinates histone H2A, a chromatin modification associated with transcriptional repression3. We find that in human breast cancer cell lines containing amplified 17q23, TRIM37 is upregulated and, reciprocally, the major H2A ubiquitin ligase RNF2 (also known as RING1B)3,4 is downregulated. Genome-wide chromatin immunoprecipitation (ChIP)-chip experiments in 17q23-amplified breast cancer cells identified many genes, including multiple tumour suppressors, whose promoters were bound by TRIM37 and enriched for ubiquitinated H2A. However, unlike RNF2, which is a subunit of polycomb repressive complex 1 (PRC1)3,4,5, we find that TRIM37 associates with polycomb repressive complex 2 (PRC2). TRIM37, PRC2 and PRC1 are co-bound to specific target genes, resulting in their transcriptional silencing. RNA-interference-mediated knockdown of TRIM37 results in loss of ubiquitinated H2A, dissociation of PRC1 and PRC2 from target promoters, and transcriptional reactivation of silenced genes. Knockdown of TRIM37 in human breast cancer cells containing amplified 17q23 substantially decreases tumour growth in mouse xenografts. Conversely, ectopic expression of TRIM37 renders non-transformed cells tumorigenic. Collectively, our results reveal TRIM37 as an oncogenic H2A ubiquitin ligase that is overexpressed in a subset of breast cancers and promotes transformation by facilitating silencing of tumour suppressors and other genes.

18 August 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SBSanchita Bhatnagar
Sanchita Bhatnagar
XZXiaochun Zhu
Xiaochun Zhu
JOJianhong Ou
Jianhong Ou
LLLing Lin
Ling Lin
LCLynn Chamberlain
Lynn Chamberlain
MGMichael R. Green
Michael R. Green
Significance: In somatic cells of female mammals, one of the two X chromosomes is randomly silenced, a phenomenon called X-chromosome inactivation (XCI). XCI is initiated in cis by a noncoding RNA called Xist , but trans -acting factors that mediate XCI remain largely unknown. In this study, we perform a large-scale RNA interference screen and identify new trans -acting factors that are required for mammalian XCI. Chemical inhibitors of some of these factors can reversibly reactivate the inactive X chromosome. Our results have therapeutic implications for certain human diseases, in particular the neurodevelopmental disorder Rett syndrome, which is caused by loss-of-function mutations in the X-linked MECP2 gene. Reactivation of the silenced wild-type MECP2 allele is a potential strategy for treating the disease.

4 December 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AVArvind M. Venkatesan
Arvind M. Venkatesan
RVRajesh Vyas
Rajesh Vyas
AGAlec K. Gramann
Alec K. Gramann
KDKaren Dresser
Karen Dresser
SGSharvari Gujja
Sharvari Gujja
CCCraig J Ceol
Craig J Ceol
Oncogenomic studies indicate that copy number variation (CNV) alters genes involved in tumor progression; however, identification of specific driver genes affected by CNV has been difficult, as these rearrangements are often contained in large chromosomal intervals among several bystander genes. Here, we addressed this problem and identified a CNV-targeted oncogene by performing comparative oncogenomics of human and zebrafish melanomas. We determined that the gene encoding growth differentiation factor 6 (GDF6), which is the ligand for the BMP family, is recurrently amplified and transcriptionally upregulated in melanoma. GDF6-induced BMP signaling maintained a trunk neural crest gene signature in melanomas. Additionally, GDF6 repressed the melanocyte differentiation gene MITF and the proapoptotic factor SOX9, thereby preventing differentiation, inhibiting cell death, and promoting tumor growth. GDF6 was specifically expressed in melanomas but not melanocytes. Moreover, GDF6 expression levels in melanomas were inversely correlated with patient survival. Our study has identified a fundamental role for GDF6 and BMP signaling in governing an embryonic cell gene signature to promote melanoma progression, thus providing potential opportunities for targeted therapy to treat GDF6-positive cancers.